Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic

被引：0
|
作者：
Giuseppe Magro
Stefania Barone
Federico Tosto
Antonio De Martino
Domenico Santange lo
Lucia Manzo
Angelo Pascarella
Pietro Bruno
Marilisa Pasquale
Antonio Gambardella
Paola Valentino
机构：
[1] University Magna Graecia of Catanzaro,Institute of Neurology
来源：
Journal of Neurology | 2023年 / 270卷
关键词：
Fatigue; Multiple sclerosis; Natalizumab wearing-off symptoms (WoS); End of dosing interval symptoms (EDIs); Extended interval dosing (ExID);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：595 / 600
页数：5
相关论文
共 16 条
  • [1] Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic
    Magro, Giuseppe
    Barone, Stefania
    Tosto, Federico
    De Martino, Antonio
    Lo, Domenico Santange
    Manzo, Lucia
    Pascarella, Angelo
    Bruno, Pietro
    Pasquale, Marilisa
    Gambardella, Antonio
    Valentino, Paola
    JOURNAL OF NEUROLOGY, 2023, 270 (02) : 595 - 600
  • [2] Natalizumab extended interval dosing: what about wearing-off effect?
    Bernardes, Catarina
    Fernandes, Catarina
    Cunha, Carolina
    Nunes, Carla
    Macario, Carmo
    Sousa, Livia
    Batista, Sonia
    Correia, Ines
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2024, 458
  • [3] Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic
    Bringeland, Gerd Haga
    Blaser, Nello
    Myhr, Kjell-Morten
    Vedeler, Christian Alexander
    Gavasso, Sonia
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [4] The natalizumab wearing-off effect End of natalizumab cycle, recurrence of MS symptoms
    van Kempen, Zoe L. E.
    Doesburg, Djoeke
    Dekker, Iris
    Lissenberg-Witte, Birgit, I
    de Vries, Annick
    Claessen, Iris A.
    ten Brinke, Anja
    Rispens, Theo
    Killestein, Joep
    NEUROLOGY, 2019, 93 (17) : E1579 - E1586
  • [5] Influence of personalized extended interval dosing on the natalizumab wearing-off effect- a sub-study of the NEXT-MS trial
    Toorop, A. A.
    Wessels, M. H. J.
    Gelissen, L. M. Y.
    Hoitsma, E.
    Zeinstra, E. M. P. E.
    van Rooij, L. C.
    van Munster, C. E. P.
    Vennegoor, A.
    Mostert, J. P.
    Wokke, B. H. A.
    Kalkers, N. F.
    Hoogervorst, E. L. J.
    van Eijk, J. J. J.
    Roosendaal, C. M.
    Kragt, J. J.
    Eurelings, M.
    van Genugten, J.
    Nielsen, J.
    Sinnige, L. G. F.
    Kloosterziel, M. E.
    Arnoldus, E. P. J.
    van Dijk, G. W.
    Bouvy, W. H.
    Strijbis, E. M. M.
    van Oosten, B. W.
    de Jong, B. A.
    Lissenberg-Witte, B. I.
    Rispens, T.
    Uitdehaag, B. M. J.
    Killestein, J.
    Kempen, Z. L. E. van
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2024, 462
  • [6] Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study
    Bringeland, Gerd Haga
    Myhr, Kjell-Morten
    Vedeler, Christian Alexander
    Gavasso, Sonia
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 415
  • [7] Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience
    Guerrieri, Simone
    Bucca, Chiara
    Nozzolillo, Agostino
    Genchi, Angela
    Zanetta, Chiara
    Cetta, Ilaria
    Rugarli, Giulia
    Gattuso, Irene
    Azzimonti, Matteo
    Rocca, Maria Assunta
    Moiola, Lucia
    Filippi, Massimo
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (09) : 2859 - 2864
  • [8] Psychopathological Symptoms Among Chronically Ill Patients During SARS-CoV-2 Pandemic in Poland
    Pawlowski, Marcin
    Fila-Witecka, Karolina
    Rymaszewska, Julia Ewa
    Kaminska, Dorota
    Poznanski, Pawel
    Augustyniak-Bartosik, Hanna
    Zielinska, Dorota
    Krajewska, Magdalena
    Krajewski, Piotr K.
    Stefaniak, Aleksandra
    Szepietowski, Jacek C.
    Pokryszko-Dragan, Anna
    Chojdak-Lukasiewicz, Justyna
    Budrewicz, Slawomir
    Pawlowski, Tomasz
    Szczesniak, Dorota
    Rymaszewska, Joanna
    PSYCHOLOGY RESEARCH AND BEHAVIOR MANAGEMENT, 2022, 15 : 2659 - 2669
  • [9] Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection
    Landi, Doriana
    Cola, Gaia
    Mantero, Vittorio
    Balgera, Roberto
    Moiola, Lucia
    Nozzolillo, Agostino
    Dattola, Vincenzo
    Sinisi, Leonardo
    Fantozzi, Roberta
    Di Lemme, Sonia
    Centonze, Diego
    Mataluni, Giorgia
    Nicoletti, Carolina Gabri
    Marfia, Girolama Alessandra
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [10] Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
    Chisari, Clara G.
    Toscano, Simona
    Arena, Sebastiano
    Finocchiaro, Chiara
    Montineri, Arturo
    Patti, Francesco
    BMC NEUROLOGY, 2021, 21 (01)
12